In a study that followed more than 500 children with attention-deficit/hyperactivity disorder (ADHD) into adulthood, extended use of stimulant medication was linked with suppressed adult height but not with reduced symptoms of ADHD.
The findings suggest that short-term treatment of ADHD with stimulant medication is well justified by benefits that outweigh costs, but long-term treatment may be associated with growth-related costs that may not be balanced by symptom-related benefits.
"The most recently published guidelines (American Academy of Pediatrics, 2011) recommend expanding the diagnosis and treatment beyond school-aged children and using stimulant medication as first-line treatment for adolescents as well as school-aged children," wrote the authors of The Journal of Child Psychology and Psychiatry study. "Since this would increase the average duration of treatment and cumulative ME dose of medication in some individuals, the findings suggest growth-related costs may increase."
Article: Young adult outcomes in the follow-up of the multimodal treatment study of attention-deficit/hyperactivity disorder: symptom persistence, source discrepancy, and height suppression, The Journal of Child Psychology and Psychiatry, James M. Swanson, L. Eugene Arnold, Brooke S. G. Molina, Margaret H. Sibley et al., The Journal of Child Psychology and Psychiatry, doi: 10.1111/jcpp.12684, published online 10 March 2017.